InfoHandle Editorial: The government should not expand Pharmaceutical Benefits Scheme safety-net relief without means testing, because the same copayment subsidy flows to high-income households that already weathered mortgage stress while low-income patients still skip scripts.
Health Minister Mark Butler flagged further indexation of safety-net thresholds before the election, arguing that medicine affordability eroded when inflation spiked in 2023. That is true for pensioners on fixed incomes. It is less convincing for dual-income households in Sydney's inner west who hit the general safety net after one specialty biologic and face no copayment cap for the rest of the calendar year.
Where the money goes
PBS spending is demand-driven: lower copayments increase scripts filled. Treasury's own data show the highest quintile of earners capture a growing share of concession-card-free scripts once thresholds fall in nominal terms. Means testing the safety net would not deny anyone treatment; it would align public subsidy with capacity to pay, the same principle applied to childcare taper rates.
Pharmacy Guild lobbying focuses on shop viability, not patient equity. Guild president Trent Twomey warns that discount pharmacies will close if reimbursement lags CPI. Independent chemists deserve fair wholesale margins, but that is a separate negotiation from whether a household earning $220,000 should pay the same $25 copayment as a disability support pensioner after crossing the threshold.
The political shortcut
Both major parties prefer universal-looking fixes because means tests invite attack ads. Yet the same politicians defend progressive income tax scales. PBS copayments are a micro-tax on illness; they should follow similar logic.
Opposition health spokeswoman Anne Ruston has criticised Labor for delaying new listings while staying silent on targeting. Silence is not a policy.
A workable model
Grattan Institute proposals to taper safety-net benefits once taxable income exceeds $100,000 would save hundreds of millions over four years without touching concession-card holders. Savings could fund faster listings for drugs stuck in price negotiation, including therapies for rare cancers where patients currently pay full private prices until PBAC approval.
Objections answered
Critics say means testing adds bureaucracy. Medicare already holds income tests for the Medicare Levy Surcharge; Services Australia could apply the same data to PBS claims in real time at the dispensary counter. Privacy safeguards exist for family tax benefit calculations and can extend here.
Others argue illness is random. So are car crashes, yet compulsory third-party insurance premiums vary by garaging postcode. Randomness does not require uniform subsidies.
What readers should watch
If Butler announces another safety-net tweak in the campaign launch, ask who benefits. Universal copayment relief sounds fair in a speech; in the ledger it often subsidises households that already chose fixed-rate mortgages before the Reserve Bank paused cuts on Wednesday's inflation print.
Patients who skip scripts because they cannot afford the first copayment need targeted help, not a blanket threshold cut. Means testing is how a rich country keeps PBS sustainable without pretending every household is equally stretched.
